BRIM Biotechnology has initiated the Phase 3 clinical trial of BRM421 for the treatment of Dry Eye Disease and enrolled the first patient in the trial. This multicenter, double-blind, randomized, vehicle-controlled trial will enroll over 700 patients.

Nanodropper launched its "2022 Give the Gift of Vision" program, which aims to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its international nonprofit partners.